Burney Co. Sells 3,302 Shares of Eli Lilly and Company $LLY

Burney Co. lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 11.8% in the 1st quarter, Holdings Channel reports. The institutional investor owned 24,758 shares of the company’s stock after selling 3,302 shares during the quarter. Eli Lilly and Company accounts for about 0.7% of Burney Co.’s portfolio, making the stock its 21st largest position. Burney Co.’s holdings in Eli Lilly and Company were worth $22,772,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Norges Bank purchased a new position in Eli Lilly and Company during the 4th quarter valued at $12,976,634,000. Capital Research Global Investors increased its stake in Eli Lilly and Company by 20.9% in the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after purchasing an additional 4,332,008 shares during the period. J. Stern & Co. LLP lifted its position in shares of Eli Lilly and Company by 46,191.3% during the fourth quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company’s stock worth $4,047,245,000 after purchasing an additional 4,038,502 shares during the last quarter. Cardano Risk Management B.V. lifted its position in shares of Eli Lilly and Company by 876.1% during the fourth quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company’s stock worth $2,552,419,000 after purchasing an additional 2,131,734 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Eli Lilly and Company by 10.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company’s stock valued at $16,024,022,000 after purchasing an additional 1,432,069 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 2.8%

NYSE LLY opened at $1,233.32 on Wednesday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The company has a market capitalization of $1.16 trillion, a price-to-earnings ratio of 43.81, a price-to-earnings-growth ratio of 1.49 and a beta of 0.51. The company’s 50-day simple moving average is $1,078.08 and its two-hundred day simple moving average is $1,030.27. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,249.45.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company’s quarterly revenue was up 55.5% on a year-over-year basis. During the same period last year, the firm earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts forecast that Eli Lilly and Company will post 35.74 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 24.58%.

Analyst Ratings Changes

A number of research firms have recently commented on LLY. Royal Bank Of Canada restated an “outperform” rating on shares of Eli Lilly and Company in a report on Thursday, May 21st. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 2nd. Rothschild & Co Redburn upped their target price on shares of Eli Lilly and Company from $880.00 to $900.00 in a research note on Thursday, May 7th. Bank of America raised their target price on shares of Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the stock a “buy” rating in a research report on Tuesday, May 26th. Finally, Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Monday, June 8th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $1,243.22.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: JPMorgan raised its price target on Eli Lilly to $1,400 from $1,300 and reiterated an overweight rating, signaling continued upside expectations for the stock. Benzinga report on JPMorgan price target raise
• Positive Sentiment: Shares hit a fresh 52-week high, reflecting momentum buying and strong investor enthusiasm around Lilly’s GLP-1 and obesity-treatment pipeline. CNBC report on Eli Lilly hitting 52-week high
• Positive Sentiment: Weak results from Kailera Therapeutics’ weight-loss pill IPO appear to have indirectly helped Lilly by reinforcing the market’s confidence in Lilly’s lead position in obesity drugs. Yahoo Finance article on Kailera setback and Lilly market cap
• Positive Sentiment: Commentary from Jim Cramer and other market-watch pieces remained constructive on biotech and Lilly’s growth story, suggesting investors still see the company as a core winner in the GLP-1 boom. 247WallSt Cramer commentary on Eli Lilly
• Neutral Sentiment: Several articles highlighted Lilly as a top healthcare stock to own and as a long-term growth story, but these were mainly opinion pieces rather than new company-specific developments. Motley Fool article on Eli Lilly stock
• Neutral Sentiment: Recent partnership and China-related business updates show Lilly is still actively managing its broader pipeline and regional strategy, but they appear less important than the obesity franchise news for today’s move. Yahoo Finance article on R&D collaboration and China rights transfer
• Negative Sentiment: Some coverage continues to point to regulatory and pricing-policy risks for Lilly, which could weigh on sentiment over time even as the stock remains strong now. Yahoo Finance article on regulatory and pricing policy challenges

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.